Le Lézard
Classified in: Health
Subject: SVY

Global POC Blood Glucose Monitoring Devices Market 2017-2021 - Growing Adoption of Minimally Invasive and Technologically Superior Products


DUBLIN, October 5, 2017 /PRNewswire/ --

The "Global POC Blood Glucose Monitoring Devices Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global POC blood glucose monitoring devices market to grow at a CAGR of 8.16% during the period 2017-2021.

Global POC Blood Glucose Monitoring Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one driver in the market is availability of CGMS and SMBG systems for POC blood glucose monitoring. With the increasing cases of diabetes globally, the need for glycemic control and modern diabetes treatment increases. Glucose monitoring is essential to keep sugar levels in check. Monitoring provides the necessary data required for diabetes management decisions related to food intake, insulin dosage, and exercise regimen. POC blood glucose monitoring devices are effective self-management tools for diabetes management.

One trend in the market is growing adoption of minimally invasive and technologically superior products. The increasing use of minimally invasive products for POC blood glucose monitoring will lead to high adoption rate among people globally. Therefore, the paradigm shift toward minimally invasive products such as wearables and screening products will increase the sales of POC blood glucose monitoring devices.

Further, the report states that one challenge in the market is high cost of diabetes management. The POC blood glucose monitoring devices are cost-efficient products. However, the healthcare expenditure for diabetes management increases the cost for the patient which leads to out-of-pocket expenditure. For screening the level of glucose, a patient has to buy a blood glucose monitoring device and an invasive device such as a lancet separately, which increases the expenditure of the individual. Consumable test strips that are used on a daily basis are expensive.

Key vendors

Other prominent vendors

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Segmentation By Product

Part 07: Market Segmentation By End-User

Part 08: Geographical Segmentation

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Key Vendor Analysis

Part 14: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/sgmpp3/global_poc_blood

Media Contact:

Laura Wood, Senior Manager
[email protected] 

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

SOURCE Research and Markets


These press releases may also interest you

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...



News published on and distributed by: